The pioneering trial used two drugs, tucatinib and trastuzumab, to treat patients with a variety of tumours linked to a protein in the body called human epidermal growth factor receptor 2, or HER2 The pioneering trial used two drugs, tucatinib and trastuzumab, to treat patients with a variety of tumours linked to a protein in the body called human epidermal growth factor receptor 2, or HER2
Breast cancer drugs could be used to shrink liver tumours in rare bile duct cancer following successful trial in Japan
